Recent studies suggested that the androgen receptor (AR) might play important roles to influence the bladder cancer (BCa) progression, yet its clinical application remains unclear.
Introduction
Bladder cancer (BCa) has a high mortality with an estimated 74690 new cases and 15580 deaths in U.S. in 2014 (1) . Most BCa patients receive the complete transurethral resection of their tumor followed by intravesical instillation of anti-tumor agents, including Bacillus Calmette-Guerin (BCG) that represents a very successful adjuvant agent for treating non-invasive BCa (2, 3) .However, the BCG therapy still has its limitations: approximately 30% of patients treated with intravesical BCG failed to respond, and for those patients with initial positive response, many suffered the high rate of recurrence (4) .Recently significant progress has been made toward understanding the mechanism of BCG anti-tumor response. With respect to the local response to BCG, growing data support a critical role for BCG/tumor interaction in initiating and directing the downstream antitumor response. By the combination of local effects and a systemic immune response, BCG therapy might have a remarkable anti-tumor effect.
Interestingly, a recent study suggested the potential linkage of androgen receptor (AR) with BCa initiation and progression (5) , and another study also indicated that androgens might be able to modulate IL-6 to alter BCG interaction with BCa cells (6) .
Here we found a new potential therapy with combination of BCG and anti-androgen hydroxyflutamide (HF) or AR degradation enhancer ASC-J9 ® better suppressed BCa progression (7) (8) (9) .
Materials and Methods
Reagents. The compound ASC-J9 ® was a gift from AndroScience Corp. BCG, a lyophilized preparation containing 10.5±8.7×10 8 colony forming units (CFU), was re-suspended in PBS.
HF was obtained from Sigma. Polyclonal antibodies against F4/80 and integrin-α5β1 were from Abcam, and BrdU was from BD. The liquid DAB+ substrate chromogen system-horseradish peroxidase used for immunocytochemistry was obtained from Dako Cytomation. Penicillin, streptomycin, MEM, and fetal bovine serum (FBS) were obtained from Invitrogen. Tris, glycine, NaCl, SDS, bovine serum albumin, and monoclonal antibody against β-actin were obtained from Sigma. Animals. FVB female mouse were obtained from the Jackson Labs. The animals were housed four per cage in a specific pathogen-free animal facility and fed with regular chow diet with water adlibitum. Animal protocols/usage was approved by the University of Rochester Committee on Animal Resources, and the mice were kept in a specific pathogen-free environment at the animal facilities of the University of Rochester Medical Center.
DNA extraction, RNA extraction, RT-PCR and Quantitative Real-Time PCR (Q-PCR)
For RT-PCR, 1μg of total RNAs were reverse-transcribed using the iScript synthesis kit GTC CAG CGC CGC TTC GG-3'(antisense); human Interleukin 6: 5'-AAG CCA GAG CTG   TGC AGA TGA GTA-3' (sense)and 5'-TGT CCT GCA GCC ACT GGT TC-3'(antisense). MTT assay. The anti-proliferative effects of HF andASC-J9 ® on BCG against BCa cell lines 253J and T24 were determined by MTT dye uptake method.
BCG attachment and internalization assay
We used PCR to detect BCG internalization and attachment to PCa cells. After incubation and washing out non-attached, excess BCG, the cells monolayer was washed twice with Hanks BSS (Gibco,). Cells were then harvested using Cell Disassociation Solution (Sigma). Genomic Statistics. Data are presented as mean ± SEM of at least 3 independent biological replicates.
The values were compared using Student's t test (two-tailed).We considered a P-value inferior to 0.05 as significant.
Results

ASC-J9
® and HF enhance BCG attachment/internalization to better suppress the BCa cells.
Early reports suggested that BCG was able to function through attachment/internalization into BCa urothelial cells to alter the immune responses to exert its chemotherapeutic effect (11) (12) (13) . Other studies also indicated that AR might play important roles to influence the BCa progression (5). We therefore decided to use two BCa urothelial cell lines (T24 and 253J) to investigate the potential impacts of the anti-androgen HF and AR degradation enhancer enhanced IL-6 expression in both T24 and 253J cells (Fig. 2C-G) . These results were in We then asked what the impacts of recruiting more monocytes/macrophages to BCa cells.
Early studies suggested that BCG might function through recruitment of macrophages to suppress BCa that involved the release of soluble cytotoxic factors, including TNF-α, IFN-γ and nitous oxide (17) . We first demonstrated that addition of BCG to theTHP-1 cells released more TNF-α compared to THP-1 only and importantly, adding ASC-J9 ® or HF released even more TNF-α compared to BCG only (Fig.3A) .Importantly, interruption approach with addition of anti-TNF-α antibody also interrupted monocytes/macrophages/BCG/HFor monocytes/macrophages/BCG/ASC-J9 ® induced BCa cell viability (Fig. 3B&C) .
Together, results from (Fig. 4A-D) .
To dissect the potential mechanism, we examined HMGB1expression as an early report (Fig. 4E) .
Together, results from Fig. 4A -E demonstrated that HF or ASC-J9 ® couldalso enhance the BCG intra-cellular efficacy to suppress BCa cell proliferation that might involve the alteration of the HMGB1 release.
ASC-J9 ® enhances the BCG efficacy to suppress BCa development in BBN-induced mouse BCa model.
We then applied BCa mouse model to prove our above in vitro cell lines findings.
12-weeks-old FVB female mice were divided into 4 groups (10 mice/group), treated with BBN (0.05%in drinking water) for 12 weeks, each group of mice were then injected with 1) vehicle control, 2) BCG alone (2×10 Using HE staining (Fig. 5A) , we found mice receiving vehicle injection developed bladder papilloma and carcinoma in situ, and BCG treated mice developed less hyperplasia with little carcinoma. Importantly, mice injected with both BCG plus ASC-J9 ® developed little hyperplasia, suggesting ASC-J9 ® indeed enhanced BCG efficacy to prevent BCa development in the BBN-induced BCa mouse model.
We also applied BrdU staining to assay the proliferation in these BBN-induced BCa mouse model and found mice treated BCG alone or ASC-J9 ® alone had less BrdU staining than those mice receiving vehicle control, and mice treated with both BCG and ASC-J9 ® had least BrdU staining (Fig. 5B&D) , which again confirmed the above findings showing ASC-J9 ® recruited many more monocytes/macrophages to BCa (Fig. 5C&E) , which is in agreement with above in vitro co-culture system (Fig. 2) showing ASC-J9 ® could enhance BCG to recruit more monocytes/macrophages to BCa cells.
Together, results from 2 nd BCa mouse model (Fig. 5C-E) clearly demonstrated that ASC-J9 ® could enhance BCG efficacy to suppress BCa development.
Discussion
BCG therapy has been used successfully to treat non-muscle invasive BCa since 1976 (2, 19, 20) . However, even BCG is quite effective, approximately 30% of BCa patients treated with intravesical BCG fail to respond [6] , and many patients have higher rate of recurrence and/or progression within five years (21, 22) .How to improve the BCG efficacy to reduce the recurrence of BCa is therefore clinically important and essential to extend the BCa patients survival.
Understanding the mechanism of BCG is critical for improving the efficacy of therapy.
Presently, it is generally assumed that the BCG-induced anti-tumor activity is critically dominated by a local nonspecific immunological reaction reflecting the activity of immunocompetent cells. After instillation, the BCG binds to fibronectin that expressed on the urothelium, which could then be internalized by the urothelial cells including cancer cells 
